Collection

Advances in Physiologically Based Pharmacokinetic (PBPK)/Biopharmaceutics (PBBM) models

Submission status
Closed
Physiologically-based pharmacokinetic (PBPK) models have seen significant adoption in the recent years to inform both drug development as well as regulatory interactions in diverse areas such as prediction of drug-drug interactions, dose predictions for first-in-human as well as special populations, and biopharmaceutics applications. This special issue highlights research across any of these areas, but with a special emphasis on absorption - a continuously evolving area.

Editors

  • Panos Macheras Panos Macheras  &

    Panos Macheras

    Panos Macheras is Professor Emeritus at National and Kapodistrian University of Athens. Currently, he is the Head of Pharmainformatics Unit of the Research Center ATHENA in Athens, Greece. He has published extensively in oral drug absorption. He recently developed the finite absorption time concept and the relevant Physiologically Based Finite Time Pharmacokinetic (PBFTPK) models.

  • Filippos Kesisoglou Filippos Kesisoglou

    Filippos Kesisoglou

    Filippos Kesisoglou is an experienced leader in the field of biopharmaceutics and formulation development, pharmacokinetics, and absorption, PBPK and IVIVC modeling as related to clinical, formulation development and CMC regulatory applications. He has in-depth knowledge of absorption, biopharmaceutics and pharmacokinetics and their implications in drug delivery and formulation development decisions for both conventional and solubilizing technologies.

Articles (10 in this collection)